Vaxart Inc. Stock
Vaxart Inc. Stock
There is nearly no change for the Vaxart Inc. stock today. Compared to yesterday it only changed by €0.000.
Our community identified positive and negative aspects for Vaxart Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Vaxart Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Vaxart Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
M***** P*******
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Vaxart Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vaxart Inc. | 0.070% | -1.958% | -26.211% | -52.834% | -58.398% | -73.770% | -95.441% |
| Larimar Therapeutics Inc. | -3.530% | 17.241% | 11.842% | -44.262% | -8.602% | -1.163% | -81.069% |
| Achieve Life Sciences Inc. | -0.130% | 2.731% | 1.282% | -6.840% | 10.799% | 65.272% | -36.800% |
| aTyr Pharma Inc | - | 16.667% | 0.000% | -81.171% | -83.192% | -69.965% | -82.902% |
Comments
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) had its "outperform" rating re-affirmed by analysts at William Blair.
Show more
Ratings data for AVIR provided by MarketBeat
News
Vaxart Revenue Jumps 520% in Fiscal Q2
Vaxart (OTC:VXRT), a biotechnology company focused on developing oral tablet vaccines for infectious diseases, reported its second quarter results on August 13, 2025. The standout headline was a
